JAGSNPHARM Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Jagsonpal Pharmaceuticals reported Q2 FY27 standalone revenue growth of 9.3% YoY to INR81 cr and consolidated revenue of INR96 cr (+29% YoY). Gross margin improved ~70 bps YoY, EBITDA margin stable at 22.7% standalone despite investments. Management expressed confidence in accelerating growth to >1.5x IPM in Q3, crossing INR100 cr quarterly revenue, and achieving INR500 cr by FY28 organically. Two acquisitions (Aequitas and Group Pharma Wellness) were completed, adding hospital channel and geographical expansion. Cash balance strong at INR135 cr. Key risks include integration execution and pricing pressure in hospital segment.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted organic growth of 9.3%, completion of two acquisitions, strong power brand performance, and a clear roadmap to INR500 cr by FY28 with margin targets, conveying confidence and strategic progress.
- Q&A Session: Neutral — Analysts questioned the aggressive INR500 cr target and margin trajectory, seeking more granular details on organic growth acceleration and integration benefits; management provided some quantification and committed to transparency, but certain responses were qualitative.
Revenue Growth Drivers
- Organic growth acceleration through power brands (e.g., Maintane +29%, Endoreg +20%)
- New product launches and portfolio expansion
- Acquisitions (Aequitas, Group Pharma Wellness) adding revenue
Growth vs Margin Focus
Management emphasizes achieving INR500 cr revenue by FY28 while improving EBITDA margins to >22% on consolidated basis through operating leverage and mix improvement.
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.